Abivax, a phase 3 clinical stage biotechnology company, develops novel therapies that modulate the body’s natural immune system to treat patients with chronic inflammatory diseases. Abivax leverages its immune enhancing platform to provide innovative and effective solutions in this therapeutic area with significant unmet medical needs. With obefazimod (ABX464), Abivax has a promising and versatile drug-candidate for the treatment of several inflammatory diseases in development. Phase 3 clinical studies with obefazimod for the treatment of ulcerative colitis (UC) will start to recruit patients by the end of September 2022. Further, obefazimod generated promising results during phase 2a studies for the treatment of rheumatoid arthritis. Obefazimod is a highly differentiated oral drug candidate, with a novel mechanism of action. In preclinical and clinical studies, the molecule has demonstrated safety and profound and maintained anti-inflammatory activities.
Abivax at a glance:
|Field of Activity||Abivax focuses on the clinical development of obefazimod in chronic inflammatory diseases, notably in inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease as well as in rheumatoid arthritis. All three diseases are very debilitating for the patients and present high medical needs, as too many patients do not respond or loose responsiveness to currently available therapies. The commercial opportunity for obefazimod in
these first chronic inflammatory indications is above USD 40B.
|Ownership Structure and Financing||Abivax is publicly listed on the Paris Stock Exchange since 2015, with Truffle Capital and Sofinnova Partners as major shareholders. The Company recently completed an oversubscribed EUR 49.2M cross-over financing with top-tier US and European biotech investors.|
|Partners||Abivax is working with IQVIA, a premier CRO, to jointly set-up and conduct the global phase 3 clinical program with obefazimod in UC.|
|Technology||Abivax is currently focusing on its phase 3 clinical program for the treatment of UC which will be conducted in 1,200 patients suffering from moderate to severe UC across 36 countries.|
|Unique Selling Point||Obefazimod is a first-in-class small molecule with the ability to selectively upregulate miR-124, a potent anti-inflammatory micro-RNA. Obefazimod has shown a good safety profile in over 1,000 patients and volunteers and impressive short-term and long-term efficacy in phase 2a and 2b studies in moderate-to-severe ulcerative colitis and in a phase 2a induction study in RA. Along with the convenient once-daily oral dosing of obefazimod, the unique mechanism of action might render this drug candidate attractive for combination therapies.|
|Date of Incorporation/
Number of Employees
|Address||7-11 Boulevard Haussmann
|Telephone/-fax||+33 1 53 83 09 63|
|Social Media||LinkedIn Twitter|